- This topic is empty.
August 4, 2013 at 5:52 am #21498CraigGParticipant
Just another update from me CraigG
1991 : First melanoma removed
2005 : Melanoma reappears
(No particular order)
3 craniotomies later
2 clinical studies
Several surgeries, radiation, etc
15th week of EMR2000066-006, 3rd clinical study
Last set of scans show no new growths, nothing getting bigger
First side effect was rash/acne on face and funny pain on scalp. I called scalp pain ‘hair on fire’
since it never lasted very long, 3-4 seconds. All under control by week 5 or so.
Very sun intolerant – Took a few weeks before it happened – Sunburned arms just going out to water plants and pick up mail…top of hands are now kinda sore…got ointments for all this
All side effects covered pretty well by my oncology staff
Never take a bunch a pills without some food – oops forgot – got the worst case of dry heaves
No major complaints – well I wish I had a bit more energy to do things..
CraigGSeptember 12, 2013 at 1:53 pm #62066
Week 21 – Good news
Most recent scans show 3 tumors inactive or gone. 2 no growth and lower activity.
My unrelated problem with my heart, Atrial Fibrillation, A-Fibs, was what was really making me think that my fatigue and shortness of breath were all related to my study drug. 6 days in hospital took care of all that. They modified my heart medications.
So now I am almost feeling normal.September 12, 2013 at 6:17 pm #62067Catherine PooleKeymaster
That all sounds good and thanks for the tips. Now, can you tell me what trial this is? I’ve not heard of this therapy and couldn’t find anything on google.September 13, 2013 at 8:43 am #62068
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Basic Trial Information
Trial Contact Information
Basic Trial Information
Phase Type Status Age Sponsor Protocol IDs
Phase I Biomarker/Laboratory analysis, Treatment Active 18 and over Pharmaceutical / Industry EMR 200066-006
This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (Mek) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian Target of Rapamycin (mTOR) inhibitor), in the treatment of locally advanced or metastatic solid tumours. The primary purpose of the study is to determine the maximum tolerated dose of the drug combination.
I’m taking it through Pinnacle Oncology, Scottsdale AZ.
Craig_GSeptember 13, 2013 at 8:57 am #62069
Forgot to specify it as a link to NCI:
- The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.